NTRK2 Fusion-Driven Neuroblastoma Treated With and Individualized Targeted Therapy Approach: A Case Report
| Authors | |
|---|---|
| Year of publication | 2025 |
| Type | Article in Periodical |
| Magazine / Source | Pediatric Hematology Oncology Journal |
| MU Faculty or unit | |
| Citation | |
| web | https://www.sciencedirect.com/science/article/pii/S2468124525003560 |
| Doi | https://doi.org/10.1016/j.phoj.2025.100788 |
| Keywords | Neuroblastoma; NTRK2 fusion; Targeted treatment; Larotrectinib; Metronomic chemotherapy |
| Attached files | |
| Description | Background We present a case of a 12-month-old female patient with metastatic neuroblastoma who was transferred to our institution after disease progression following two cycles of standard treatment in Ukraine. Upon admission, the child was critically ill, presenting with a large abdominal mass, severe cachexia, deep vein thrombosis with limb oedema, and oxygen dependency due to limited chest excursions. Case report After initial stabilization, comprehensive genomic profiling revealed an SRGAP3:NTRK2 gene fusion in the tumor sample. An individualized combination of standard chemotherapy, targeted treatment with larotrectinib, and metronomic chemotherapy was administered. This regimen resulted in a radiologically confirmed partial response and a notable clinical improvement. Conclusion This case documents a rare instance of NTRK2 fusion-driven neuroblastoma successfully treated with a regimen containing a pan-TRK inhibitor that proved to be well-tolerated and effective. |
| Related projects: |